Search results for "Cyclin"

showing 10 items of 1021 documents

Regeneration of total RNA purification silica-based columns

2010

Silica-based columns are largely used in RNA purification, allowing fast extractions and good yields of high quality nucleic acid, but their major limitation is the high cost. The reuse of such columns, although desirable, is not recommended because of residual amounts of material from the previous sample trapped in the column matrix, which might be released during further purification. Thus, recycling does need previous complete removal of any detectable RNA trace, but to date no protocol which allows decontamination and reuse is available.We report a very rapid decontamination procedure, based on treatment with warm alkaline solution containing Triton X-100, which ensures no RNA carry-ove…

OctoxynolClinical BiochemistryTotal rnatotal RNA purificationSettore BIO/11 - Biologia MolecolareReuseAlkaliesBiochemistryAnalytical ChemistrySettore BIO/10 - BiochimicaDrug DiscoveryRecyclingalkaline treatmentMolecular BiologyDecontaminationPharmacologyColumn vectorChromatographyChromatographyChemistryRegeneration (biology)RNAGeneral MedicineHuman decontaminationsilica-based spin-columSilicon DioxideregenerationNucleic acidRNARNA extractionTriton-X 100 treatment
researchProduct

Conventional induction and post-remission therapy in APL: have we arrived?

2014

Since the introduction of all-trans-retinoic acid, the use of this molecularly targeted treatment in combination with anthracycline-based chemotherapy has completely changed the prognosis of acute promyelocytic leukemia (APL) turning it into the most curable acute myeloid leukemia. Also, the use of risk-adapted protocols has optimized the drug combination and the most appropriate dose intensity for each subset of patients classified according to both risk of relapse and vulnerability to drug toxicity. Recent developments have included the investigation of the role of arsenic trioxide (ATO) as front-line treatment after its success in relapsed APL, both to minimize or even omit the use of cy…

OncologyAcute promyelocytic leukemiaDrugmedicine.medical_specialtyHarringtoninesAnthracyclinemedia_common.quotation_subjectmedicine.medical_treatmentClinical BiochemistryTretinoinPharmacologyArsenicalsTargeted therapyMaintenance Chemotherapychemistry.chemical_compoundArsenic TrioxideLeukemia Promyelocytic AcuteInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMulticenter Studies as TopicAnthracyclinesRelapse riskArsenic trioxidemedia_commonChemotherapyClinical Trials as Topicbusiness.industryMercaptopurineDaunorubicinRemission InductionMyeloid leukemiaOxidesmedicine.diseaseConsolidation ChemotherapyMethotrexateOncologychemistryMitoxantronebusinessHomoharringtonineIdarubicinBest practiceresearch. Clinical haematology
researchProduct

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in pati…

2015

Aim: Breast International Group (BIG) 2-98 is a randomised phase III trial that tested the effect of adding docetaxel, either in sequence to or in combination with anthracycline-based adjuvant chemotherapy, in women with node-positive breast cancer (BC). Here, we present the 10-year final trial safety and efficacy analyses. We also report an exploratory analysis on the predictive value of Ki67 for docetaxel efficacy, in the BIG 2-98 and using a pooled analysis of three other randomised trials. Patients and methods: 2887 patients were randomly assigned in a 2 x 2 trial design to one of four treatments. The primary objective was to evaluate the overall efficacy of docetaxel on disease free su…

OncologyAdultAdjuvant taxanesCancer Researchmedicine.medical_specialtyAnthracyclinemedicine.medical_treatmenteducationBreast NeoplasmsDocetaxelDisease-Free SurvivalPooled analysisBreast cancerBreast cancerPredictive Value of TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansIn patientAnthracyclinesOestrogen receptorProspective StudiesAgedER positivebusiness.industryMiddle Agedmedicine.diseaseImmunohistochemistryPooled analysisKi-67 AntigenOncologyDocetaxelBreast international groupChemotherapy AdjuvantFemaleTaxoidsbusinessAdjuvantKi67medicine.drug
researchProduct

Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph node…

2014

Abstract Aim Adjuvant chemotherapy has changed dramatically in the last decades. Anthracycline-/Taxane-based and dose-dense chemotherapy regimens improved survival in node positive breast cancer. This study tries to answer the following questions: (1)Are there differences in survival dependent on chemotherapy regimens in stratified by number of positive lymph nodes/grading (G)/hormone receptor-status (HR)/T-stage? (2)Is it possible to attribute these effects to chemotherapy by only investigating patients who received 100% guideline-conform surgery, radiotherapy and endocrine therapy? Methods This is a German multi-centre (17 participating hospitals all certified as breast cancer centres) re…

OncologyAdultBridged-Ring CompoundsCancer Researchmedicine.medical_specialtyNeoplasms Hormone-DependentAxillary lymph nodesAnthracyclineDose-dense chemotherapyReceptor ErbB-2medicine.medical_treatmentBreast NeoplasmsDisease-Free SurvivalYoung AdultBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAnthracyclinesAgedRetrospective StudiesAged 80 and overChemotherapyAnalysis of VarianceTaxanebusiness.industryRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryRadiation therapymedicine.anatomical_structureTreatment OutcomeOncologyChemotherapy AdjuvantLymphatic MetastasisPractice Guidelines as TopicFemaleTaxoidsGuideline AdherencebusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Mitomycin 'C' and vinorelbine as second line chemotherapy for metastatic breast carcinoma

1994

Aims and background Patients with metastatic breast carcinoma resistant to first line chemotherapy may require further treatment. Results o second line chemotherapy are still largerly unsatisfactory. For this reason a phase II study on the combination of mitomycin C and vinorelbine was carried out. Methods Forty patients with anthracycline pretreated metastatic breast cancer were treated with a combination of mitomycin C 10 mg/m2 i.v. on day 1, and vinorelbine 25 mg/m2 i.v. on days 1 and 8. This cycle was repeated every 28 days. Responses were evaluated according to the WHO criteria. Results A major objective response was recorded in 16 cases (40%; 95% confidence limits 32%-48%), with 2 pat…

OncologyAdultCancer Researchmedicine.medical_specialtyAnthracyclineMitomycinPhases of clinical researchBreast NeoplasmsVinorelbineVinblastineGastroenterologyDrug Administration Schedule030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineRefractoryInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedLeukopeniabusiness.industryMitomycin CCarcinomaVinorelbineGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerTreatment OutcomeOncology030220 oncology & carcinogenesisFemalemedicine.symptombusinessProgressive diseasemedicine.drug
researchProduct

Treatment of metastatic breast cancer with vinorelbine and docetaxel.

2006

Objective: A phase II study was performed to evaluate efficacy and safety of the combination vinorelbine and docetaxel in patients with metastatic breast cancer previously treated with anthracycline-based regimens. Overall 41 patients were included in the study. Methods: Treatment consisted of vinorelbine 25 mg/m 2 and docetaxel 75 mg/m 2 , both administered on day 1 every 3 weeks for a maximum of 9 cycles. Most patients (92%) were postmenopausal with a median age of 57 years, and median ECOG performance of 1. Sites of disease were viscera in 42% of patients, bones in 30%, soft-tissues in 32%. Sixty-five percent of patients had >2 metastatic sites. Previous treatments included neo-adjuvant …

OncologyAdultCancer Researchmedicine.medical_specialtyDocetaxel; Metastatic breast cancer; VinorelbineAnthracyclinemedicine.medical_treatmentPhases of clinical researchBreast NeoplasmsDocetaxelNeutropeniaVinorelbineVinblastineGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMucositisMedicineHumansInfusions IntravenousChemotherapybusiness.industryVinorelbineMiddle Agedmedicine.diseaseMetastatic breast cancerMetastatic breast cancerSurvival AnalysisTreatment OutcomeOncologyDocetaxelDisease ProgressionFemaleTaxoidsbusinessmedicine.drugAmerican journal of clinical oncology
researchProduct

Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities.

1999

In the present study, the expression of cyclin D1, as detected by immunohistochemistry, was compared with other prognostic variables and its prognostic impact was evaluated in a group of 172 patients with squamous cell carcinoma (SCC) of the esophagus who underwent potentially curative resection therapy and in a second group of 38 patients with SCC of the esophagus who were treated by combined modality therapy (radiochemotherapy ± surgery). Expression of cyclin D1 in surgically treated carcinomas correlated negatively with tumor differentiation (p = 0.026) but positively with mitotic activity (p = 0.0199) and nodal status (p = 0.040). There were no significant correlations with pT category.…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPrognostic variableEsophageal Neoplasmsmedicine.medical_treatmentLeucovorinCyclin D1EsophagusInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansCyclin D1EsophagusAgedEpirubicinAged 80 and overMucous MembraneEsophageal diseasebusiness.industryCancerEsophageal cancerMiddle Agedmedicine.diseasePrognosisCombined Modality TherapySurgeryRadiation therapySurvival Ratemedicine.anatomical_structureOncologyEpidermoid carcinomaCarcinoma Squamous CellFemaleFluorouracilCisplatinbusinessInternational journal of cancer
researchProduct

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study…

2013

Abstract Background We evaluated the pathological complete response (pCR) rate after neoadjuvant epirubicin, (E) cyclophosphamide (C) and docetaxel containing chemotherapy with and without the addition of bevacizumab in patients with triple-negative breast cancer (TNBC). Patients and methods Patients with untreated cT1c-4d TNBC represented a stratified subset of the 1948 participants of the HER2-negative part of the GeparQuinto trial. Patients were randomized to receive four cycles EC (90/600 mg/m2; q3w) followed by four cycles docetaxel (100 mg/m2; q3w) each with or without bevacizumab (15 mg/kg; q3w) added to chemotherapy. Results TNBC patients were randomized to chemotherapy without (n =…

OncologyAdultmedicine.medical_specialtyBevacizumabCyclophosphamideAnthracyclinePaclitaxelmedicine.medical_treatmentTriple Negative Breast NeoplasmsAntibodies Monoclonal HumanizedYoung AdultBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesEverolimusCyclophosphamideAgedEpirubicinUltrasonographySirolimusChemotherapyTaxanebusiness.industryCarcinoma Ductal BreastHematologyMiddle Agedmedicine.diseaseNeoadjuvant TherapyTumor BurdenBevacizumabTreatment OutcomeOncologyDocetaxelChemotherapy AdjuvantMultivariate AnalysisFemalebusinessmedicine.drugEpirubicinAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicent…

2016

Elderly breast cancer patients are affected by poorer quality of life (QoL) compared to younger patients. Because QoL has a relevant impact on guideline-adherent treatment, elderly breast cancer patients are often undertreated, especially with regard to adjuvant chemotherapy, and overall survival is decreased. Thus, understanding the impact of chemotherapy on QoL in elderly patients is crucial. This study compared QoL in patients aged 65 years and 65 to 70 years receiving adjuvant chemotherapy as a secondary outcome in the prospective randomized multicenter ADEBAR trial.Patients with lymph node-positive breast cancer were prospectively randomized for either sequential anthracycline-taxane o…

OncologyCancer ResearchDocetaxel0302 clinical medicineQuality of lifeSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsMulticenter Studies as TopicAnthracyclinesLongitudinal StudiesProspective Studies030212 general & internal medicineYoung adultProspective cohort studyAntibiotics AntineoplasticAge FactorsMiddle AgedhumanitiesOncologyDocetaxelChemotherapy Adjuvant030220 oncology & carcinogenesisPractice Guidelines as TopicFemaleTaxoidsFluorouracilmedicine.drugEpirubicinAdultBridged-Ring Compoundsmedicine.medical_specialtyAdolescentCyclophosphamideBreast NeoplasmsYoung Adult03 medical and health sciencesBreast cancerInternal medicinemedicineHumansCyclophosphamideAgedEpirubicinbusiness.industryCancermedicine.diseaseClinical Trials Phase III as TopicQuality of LifePatient CompliancebusinessClinical Breast Cancer
researchProduct

The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population

2013

<b><i>Background:</i></b> Breast cancer in the elderly is associated with high recurrence and death rates, due mostly to undertreatment. Human epidermal growth factor receptor type 2 (HER2) overexpression is infrequent in older patients. Trastuzumab-based chemotherapy is often withheld from elderly patients because of its cardiotoxicity. <b><i>Patients and Methods:</i></b> Medical records of consecutive HER2-positive breast cancer patients aged ≥70 years old treated between 2005 and 2010 in the participating centers were retrospectively reviewed. All patients underwent multidimensional geriatric assessment (MGA). <b><i>Results:<…

OncologyCancer Researchmedicine.medical_specialtyAnthracyclineSettore MED/06 - Oncologia MedicaReceptor ErbB-2medicine.medical_treatmentPopulationAntineoplastic AgentsBreast NeoplasmsAntibodies Monoclonal HumanizedVentricular Function LeftBreast cancer; Elderly patients; Human epidermal growth factor receptor type 2; TrastuzumabBreast cancerBreast cancerTrastuzumabInternal medicinemedicineHumansAdverse effecteducationGeriatric AssessmentAgedRetrospective StudiesAged 80 and overChemotherapyCardiotoxicityeducation.field_of_studybusiness.industryRetrospective cohort studyGeneral MedicineTrastuzumabmedicine.diseaseHuman epidermal growth factor receptor type 2OncologyFemalebusinessElderly patientmedicine.drugOncology
researchProduct